This increase in the synthesis of lipoprotein lipase thereby increases the clearance of triglycerides. Humans also have several related enzymes, including hepatic lipase, endothelial lipase, and lipoprotein lipase. Cholesterol is delivered into the vessel wall by cholesterol-containing low-density lipoprotein (LDL) particles. Conversely, it has little effect on levels of triglycerides and high-density lipoprotein (HDL). Health issues include high levels of low-density lipoprotein, high total cholesterol, and weight loss. APOC2 is the coenzyme for lipoprotein lipase (LPL) activity. Among these are the low-density lipoprotein (LDL) receptor and HMG-CoA reductase. ACTH also stimulates lipoprotein uptake into cortical cells. Once in the blood, chylomicrons are subject to delipidation by lipoprotein lipase. It belongs to the Low density lipoprotein receptor gene family. VLDL is converted in the bloodstream to low-density lipoprotein (LDL) and intermediate-density lipoprotein (IDL). Glybera treats one such disease, caused by a defect in lipoprotein lipase. They decrease VLDL - very low density lipoprotein - and LDL in some people. It is a key protein in the exogenous pathway of lipoprotein metabolism. Release from the hepatocyte may involve the very low density lipoprotein secretory pathway.